FDA OKs Tolvaptan for Rapidly Progressing Rare Kidney Disease FDA OKs Tolvaptan for Rapidly Progressing Rare Kidney Disease

Because of the risks for serious liver injury, tolvaptan is available only through a restricted distribution program supported by a risk evaluation and mitigation strategy program approved by the FDA.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Alert Source Type: news